TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34712117
Drug: Retinal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retinal oxygen metabolism assessment in RMS patients
Study: 34712229
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Radiation Therapy (LDRT) with a single dose per fraction of 0.5Gy
Study: 34712229
Drug: Low Dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Dose Radiation Therapy (LDRT)
Study: 34712513
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment with intravenous PD-1 inhibitor toripalimab (240 mg), carboplatin (AUC 5), and pemetrexed (500 mg/m2) for three cycles.
Study: 34712928
Drug: Direct-acting antivirals
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals (DAAs) - sofosbuvir with an NS5A inhibitor (ledipasvir, daclatasvir or velpatasvir)±ribavirin
Study: 34712959
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (letrozole) combined with CDK inhibitor ribociclib
Study: 34712959
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy (letrozole) alone
Study: 34713017
Drug: Internet Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet Cognitive Behavioral Therapy with additional face-to-face outpatient psychotherapy (ICBT+)
Study: 34713017
Drug: Internet Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet Cognitive Behavioral Therapy without additional face-to-face outpatient psychotherapy (ICBT)
Study: 34713415
Drug: Tapinarof cream
Normalized name: tapinarof Topical Cream
DrugBank: Tapinarof (DB06083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tapinarof cream 1% QD for 29 days
Study: 34713782
Drug: Statin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin treatment in patients with ischemic heart disease (IHD)
Study: 34713782
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor antagonists in patients with IHD, arterial hypertension, chronic heart failure (CHF), and atrial fibrillation
Study: 34713782
Drug: Beta-blockers in
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers in patients with IHD, arterial hypertension, chronic heart failure (CHF), and atrial fibrillation
Study: 34713782
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants (OAC), primarily direct OAC, clopidogrel/prasugrel/ticagrelor in patients with IHD
Study: 34713782
Drug: Oral antihyperglycemic
Normalized name: ANTIHYPOGLYCEMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antihyperglycemic therapy in patients with type 2 diabetes mellitus (DM)
Study: 34713782
Drug: Spironolactone treatment
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone treatment in patients with CHF
Study: 34713782
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (iCS) in patients with chronic obstructive pulmonary disease (COPD)
Study: 34714555
Drug: Pomalidomide plus
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide plus low-dose dexamethasone (POM/DEX)
Study: 34714708
Drug: Craniospinal RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craniospinal RT dose of 23.4 Gy for average-risk patients and 36-39.6 Gy for high-risk patients, boost dose of 55.8 Gy to the tumor bed.
Study: 34714708
Drug: Increasing RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing RT dose to the corpus callosum (CC) or frontal white matter (WM) and hippocampus.
Study: 34716177
Drug: Adavosertib 300
Normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adavosertib 300 mg daily on days 1 through 5 and 8 through 12 of a 21-day cycle
Study: 34716198
Drug: Ipilimumab (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipilimumab (1 mg/kg i.v. every 6 weeks) plus Nivolumab (240 mg i.v. every 2 weeks)
Study: 34716965
Drug: Ultrasound-guided conventional
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided conventional radiofrequency (RF) treatment of the genicular nerves
Study: 34717057
Drug: Serum anti-Müllerian
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum anti-Müllerian hormone (AMH) levels measured using the Elecsys AMH Plus immunoassay
Study: 34717608
Drug: Non-ablative radiofrequency
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-ablative radiofrequency (RF) treatment (41°C) for five sessions with one week intervals
Study: 34717717
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy plus chemoradiotherapy (experimental group)
Study: 34717717
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy alone (control group)
Study: 34718447
Drug: Oral treprostinil
Normalized name: Treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral treprostinil for 1 year
Study: 34718493
Drug: Warfarin (INR:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (INR: 2-2.5) and Aspirin (withheld after first bleeding episode)
Study: 34718493
Drug: Post-implant vWf:Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-implant vWf:Ag and vWf:CB
Study: 34718501
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for post-infarction PMR with mitral valve replacement and concomitant coronary artery bypass grafting (CABG) in 57% of cases.
Study: 34718501
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for post-infarction PMR.
Study: 34718501
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for post-infarction PMR with concomitant CABG.
Study: 34718636
Drug: Higher antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher antibodies to Ae. aegypti salivary proteins
Study: 34718859
Drug: High-LA diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-LA diet (30, 40, or 50 ml of sunflower oil daily for 4 weeks)
Study: 34718859
Drug: High-LA diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-LA diet (30, 40, or 50 ml of sunflower oil daily for 4 weeks) in FADS1 rs174550-CC genotype
Study: 34718884
Drug: NOAC (non-vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: NOAC (non-vitamin K-dependent oral antagonists)
Study: 34718884
Drug: In-hospital treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital treatment after stroke
Study: 34719198
Drug: Repeated intrathecal
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated intrathecal injections of autologous mesenchymal stem cells, dosage and duration not available
Study: 34722242
Drug: AGIG chemo-immunotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGIG chemo-immunotherapy regimen (nab-paclitaxel + gemcitabine + IL-2 + GM-CSF)
Study: 34722269
Drug: Regionally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regionally administered melphalan
Study: 34722563
Drug: MMGA (multimodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMGA (multimodal general anesthesia) using intravenous remifentanil, ketamine, dexmedetomidine, magnesium, and bupivacaine as a pecto-intercostal fascial block.
Study: 34722661
Drug: Anti-inflammatory medications,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-inflammatory medications, specific type and dosage not available
Study: 34722810
Drug: Moderately hypofractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately hypofractionated intensity-modulated proton therapy (IMPT) targeting the prostate/seminal vesicles and pelvic lymph nodes, 6750 cGyRBE for prostate and 4500 cGyRBE for pelvic lymph nodes in 25 daily fractions, all received androgen-deprivation therapy.
Study: 34724115
Drug: 4SCAR-GD2 T-cell
Normalized name: CD4CAR T cells
DrugBank: Anti-CD4 CAR T-cell therapy (DB17281)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4SCAR-GD2 T-cell treatment
Study: 34724226
Drug: Molibresib 75
Normalized name: Molibresib
DrugBank: Molibresib (DB16239)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molibresib 75 mg once daily
Study: 37587492
Drug: Intravenous arginine
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous arginine therapy
Study: 34724453
Drug: Daily step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily step counts measured using armband accelerometers worn for 7 days, with a median of 1170 steps daily.
Study: 34724453
Drug: Daily step
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily step counts measured using armband accelerometers worn for 7 days.
Study: 34725072
Drug: IV DEXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV DEXA (24 mg)
Study: 34725077
Drug: In-bed leg
Normalized name: Crab leg
DrugBank: Crab leg (DB11011)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-bed leg cycling for 30 minutes daily for 14 consecutive days, initiated within 48 hours of spinal surgery.
Study: 34725108
Drug: mTOR inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR inhibitors (mTORis)
Study: 34725289
Drug: Tregocel® nutraceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tregocel® nutraceutical supplement
Study: 34726610
Drug: Peer-delivered eHealth
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer-delivered eHealth intervention (3 sessions delivered weekly over 3 weeks)
Study: 34726887
Drug: SY-5609, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: SY-5609, a selective, noncovalent inhibitor of CDK7
Study: 34727366
Drug: HS-10234 25
Normalized name: sodium fluoride 0.00234 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10234 25 mg daily for 7 days (D1-D7) followed by emtricitabine 200 mg QD for 7 days (D8-D14)
Study: 34727366
Drug: Emtricitabine 200
Normalized name: emtricitabine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine 200 mg QD for 7 days (D1-D7) followed by HS-10234 25 mg QD for 7 days (D8-D14)
Study: 34727875
Drug: nab-paclitaxel (Abraxane,
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel (Abraxane, 125 mg/m2, D1, D8, D15 every 28 days)
Study: 34727956
Drug: MedReviewRx software
Approvals — FDA: no, EMA: no, PMDA: no
Description: MedReviewRx software used for medication reviews
Study: 34728052
Drug: Mandibular advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular advancement device therapy
Study: 34728440
Drug: Monthly videoconference-psychotherapy
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly videoconference-psychotherapy
Study: 34728440
Drug: Weekly videoconference-psychotherapy
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly videoconference-psychotherapy plus message-based care
Study: 34729148
Drug: Non-Optimal Medical
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Optimal Medical Therapy (non-OMT)
Study: 34729767
Drug: Hyperfibrinolysis defined
Normalized name: refined almond oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperfibrinolysis defined as enzymatic fibrinolysis index (ROTEM EXTEM ML minus ROTEM APTEM ML) above 15%
Study: 34730535
Drug: Smartphone-enhanced behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone-enhanced behavioral activation treatment (Life Enhancement Treatment for Substance Use)
Study: 34730541
Drug: Online therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online therapy
Study: 34730541
Drug: Face-to-Face therapy
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-Face therapy (F2F)
Study: 34732500
Drug: Lengthened dosing
Normalized name: PROPYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Eyelash and Eyebrow Lengthener]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lengthened dosing interval (from 8 to 12 weeks for infliximab users and from 2 to 3 weeks for adalimumab users)
Study: 34732500
Drug: Lengthened dosing
Normalized name: PROPYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Eyelash and Eyebrow Lengthener]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lengthened dosing interval
Study: 34732682
Drug: Atazanavir 300
Normalized name: atazanavir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 300 mg and Cobicistat 150 mg orally once daily during the second trimester
Study: 34732682
Drug: Atazanavir 300
Normalized name: atazanavir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 300 mg and Cobicistat 150 mg orally once daily during the third trimester
Study: 34732682
Drug: Atazanavir 300
Normalized name: atazanavir 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir 300 mg and Cobicistat 150 mg orally once daily postpartum
Study: 34734199
Drug: Treatment-as-usual services
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual services
Study: 34734223
Drug: Light drinkers
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light drinkers (>2 to 10 g/d)
Study: 34734223
Drug: Moderate drinkers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate drinkers (>10 to 30 g/d)
Study: 34734223
Drug: Heavy drinkers
Normalized name: heavy mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heavy drinkers (>30 g/d)
Study: 34734223
Drug: Nondrinkers (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondrinkers (0 g/d) and very light drinkers (>0 to 2 g/d)
Study: 34734507
Drug: Drug-induced IL-22
Normalized name: Ile
DrugBank: Isoleucine (DB00167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-induced IL-22 releasing cells
Study: 34734507
Drug: Drug-induced IFN-γ
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-induced IFN-γ releasing cells
Study: 34734507
Drug: Drug-induced GrB
Normalized name: GRb 1
DrugBank: Ginsenoside Rb1 (DB06749)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-induced GrB releasing cells
Study: 34734835
Drug: 12 sessions
Normalized name: Alpinia Sessilis Root
DrugBank: Kaempferia galanga root (DB14288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 sessions of twice weekly EMDR plus treatment as usual
Study: 34735860
Drug: Acalabrutinib 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acalabrutinib 200 mg twice daily as monotherapy
Study: 34736130
Drug: Extended-release buprenorphine
Normalized name: Buprenorphine Extended-Release Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release buprenorphine injections (BUP-XR), administered monthly after a minimum of 7 days on 8-32 mg of sublingual buprenorphine (±naloxone)
Study: 34736497
Drug: Scalp nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp nerve blocks with 0.5% bupivacaine plus dexamethasone (exact dosage not specified)
Study: 34736503
Drug: Conductive hearing
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conductive hearing loss or combination of conductive and sensorineural hearing loss
Study: 34736538
Drug: Idiographic network
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idiographic network analysis for personalized treatment targets
Study: 34736538
Drug: Selection methods
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selection methods for treatment targets
Study: 34736789
Drug: Preoperative soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative soluble urokinase plasminogen activator receptor
Study: 34736789
Drug: Preoperative soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative soluble urokinase plasminogen activator receptor between 5.5 and 10 ng/mL
Study: 34736789
Drug: Preoperative soluble
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative soluble urokinase plasminogen activator receptor >10 ng/mL
Study: 34736789
Drug: Receiver operating
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiver operating characteristic analysis of soluble urokinase plasminogen activator receptor
Study: 34736789
Drug: Adding soluble
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adding soluble urokinase plasminogen activator receptor to the model
Study: 34737035
Drug: Persistently low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persistently low hsCRP (hsCRP ≤ 2 mg/L)
Study: 34737035
Drug: Persistently high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Persistently high hsCRP (hsCRP > 2 mg/L)
Study: 34738141
Drug: Bevacizumab-800CW (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab-800CW (10 mg intravenously administered 3 days prior to surgery)
Study: 34739527
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g Vitamin C 4 times a day during 4 days, started within 6 hours after admission
Study: 36037567
Drug: Lurbinectedin 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurbinectedin 3.2 mg/m
Study: 34739844
Drug: Ibrutinib plus
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib plus R-CHOP chemotherapy
Study: 34739844
Drug: R-CHOP chemotherapy
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP chemotherapy alone
Study: 34740768
Drug: Salvage low-dose-rate
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salvage low-dose-rate (LDR) prostate brachytherapy (BT)
Study: 34741102
Drug: IV sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV sildenafil 0.25 mg/kg (cohort 2)
Study: 34741102
Drug: IV sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV sildenafil 0.125 mg/kg (cohort 2)
Study: 34741172
Drug: CAPA-AREG (medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPA-AREG (medium with amphiregulin 100 ng/ml)
Study: 34741321
Drug: Transcortical miniscrew
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcortical miniscrew placed over the buccal plate of the extraction socket
Study: 34741822
Drug: Permanent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permanent treatment discontinuation
Study: 34741822
Drug: Dose or
Normalized name: Oxydose Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose or regimen adjustment
Study: 34742157
Drug: BNT162b2 SARS-CoV-2
Normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 SARS-CoV-2 vaccination (two doses)
Study: 34745093
Drug: Dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase alfa (inhaled)
Study: 34746207
Drug: Infliximab treatment
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab treatment without Vitamin D3 supplementation
Study: 34746903
Drug: Bempedoic acid
Normalized name: bempedoic acid
DrugBank: Bempedoic acid (DB11936)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bempedoic acid 180 mg plus ezetimibe 10 mg fixed-dose combination (BA + EZE FDC)
Study: 34747267
Drug: Topical Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Oxygen Therapy (Natrox)
Study: 34748385
Drug: Clofazimine, dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clofazimine, dosage and duration not specified
Study: 34748634
Drug: Severe insulin-resistant
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Severe insulin-resistant diabetes (SIRD)
Study: 34748672
Drug: Ocrelizumab 600
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ocrelizumab 600 mg intravenous every 24 weeks for 96 weeks
Study: 34748951
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml Extra Virgin Olive Oil (EVOO) daily for one year
Study: 34748951
Drug: Not administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not administered EVOO (Control group)
Study: 34749777
Drug: Personalized pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Personalized pharmaceutical plan (PPP) implemented in the intervention phase, including drug reconciliation, daily follow-up, and post-transplantation meetings.
Study: 34749777
Drug: Control phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control phase with no personalized pharmaceutical plan.
Study: 34749788
Drug: Home-based diabetes-modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based diabetes-modified behavioral activation treatment (HOME DM-BAT) using in-home, nurse telephone-delivered diabetes education and behavioral activation.
Study: 34749788
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care group using in-home, nurse telephone-delivered health education/supportive therapy.
Study: 34749885
Drug: Checkpoint inhibitor
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Checkpoint inhibitor therapy
Study: 34750057
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray (ESK) plus oral antidepressant during induction phase (4 weeks)
Study: 34750057
Drug: Esketamine nasal
Normalized name: esketamine Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esketamine nasal spray (ESK) plus oral antidepressant during optimization/maintenance phase (week 12)
Study: 34750057
Drug: Treatment-emergent adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent adverse events (TEAEs) during induction phase
Study: 34750057
Drug: Treatment-emergent adverse
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-emergent adverse events (TEAEs) during optimization/maintenance phase